JPRN-C000000308已完成2 期
Phase II study of gemcitabine alone in locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG 0506) - Phase II study of gemcitabine alone in locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG 0506)
Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 50 人开始时间: 2006年1月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients are excluded if they meet the following criteria: They have obvious ascetic or pleural effusion, lung fibrosis or pneumonitis, uncontrolled diabetes mellitus in spite of using more than 40 unit insulin, Classification of New York Heart Association (NYHA) of III or IV, myocardial infarction within 6 months before this trial, synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ, or severe mental disease.
研究者
相似试验
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in advanced biliary tract cancer. (JCOG 0805)biliary tract neoplasmJPRN-UMIN000001685Japan Clinical Oncology Group(JCOG)100
已完成
2 期
Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901)Refractory relpased small-cell lung cancerJPRN-UMIN000002763Japan Clinical Oncology Group(JCOG)80
已完成
2 期
Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)JPRN-UMIN000005342Japan Clinical Oncology Group (JCOG)80
已完成
2 期
Randomized phase II study of the Induction Chemotherapy with Docetaxel alone vs CDDP+Docetaxel for c-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)JPRN-C000000032Japan Clinical Oncology Group(JCOG)80
已完成
2 期
Randomized phase II study of two induction treatments of melphalan, prednisolone, plus bortezomib, JCOG-MPB versus modified PETHEMA-MPB, in elderly patients or non-elderly patients refusing transplant with untreated symptomatic myeloma(JCOG1105, IMPROVE-MPB study)Elderly patients or non-elderly patients refusing transplant with untreated symptomatic myelomaJPRN-UMIN000011180Japan Clinical Oncology Group (JCOG)91